These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 38541119)
1. Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures. Wikarek A; Grabarczyk M; Klimek K; Janoska-Gawrońska A; Suchodolska M; Holecki M Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541119 [TBL] [Abstract][Full Text] [Related]
2. The impact of diabetes and diabetes medications on bone health. Gilbert MP; Pratley RE Endocr Rev; 2015 Apr; 36(2):194-213. PubMed ID: 25738213 [TBL] [Abstract][Full Text] [Related]
3. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337 [TBL] [Abstract][Full Text] [Related]
4. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315 [TBL] [Abstract][Full Text] [Related]
5. Pharmacologic Therapy of Type 2 Diabetes. Wright JJ; Tylee TS Med Clin North Am; 2016 Jul; 100(4):647-63. PubMed ID: 27235609 [TBL] [Abstract][Full Text] [Related]
7. Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach. Brønden A; Christensen MB; Glintborg D; Snorgaard O; Kofoed-Enevoldsen A; Madsen GK; Toft K; Kristensen JK; Højlund K; Hansen TK; Søndergaard E; Hansen KB Diabet Med; 2023 Aug; 40(8):e15157. PubMed ID: 37249579 [TBL] [Abstract][Full Text] [Related]
8. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors]. Verburg AFE; van den Donk M; Wiersma T Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706 [TBL] [Abstract][Full Text] [Related]
9. Recommendations on the effect of antidiabetic drugs in bone. Rozas-Moreno P; Reyes-García R; Jódar-Gimeno E; Varsavsky M; Luque-Fernández I; Cortés-Berdonces M; Muñoz-Torres M; Endocrinol Diabetes Nutr; 2017 Mar; 64 Suppl 1():1-6. PubMed ID: 28440761 [TBL] [Abstract][Full Text] [Related]
10. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis. Zhou JB; Tang X; Han M; Yang J; Simó R Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679 [TBL] [Abstract][Full Text] [Related]
11. What to add in with metformin in type 2 diabetes? Petrie JR; Adler A; Vella S QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663 [TBL] [Abstract][Full Text] [Related]
12. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Tong L; Adler S Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921 [TBL] [Abstract][Full Text] [Related]
13. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors. Kumar A Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862 [TBL] [Abstract][Full Text] [Related]
14. Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis. Tan L; Wang Z; Okoth K; Toulis KA; Denniston AK; Singh BM; Crowe FL; Sainsbury C; Wang J; Nirantharakumar K Front Endocrinol (Lausanne); 2023; 14():1303238. PubMed ID: 38239984 [TBL] [Abstract][Full Text] [Related]
15. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. Chang HY; Singh S; Mansour O; Baksh S; Alexander GC JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373 [TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618 [TBL] [Abstract][Full Text] [Related]
17. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124 [TBL] [Abstract][Full Text] [Related]
18. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study. Rathmann W; Bongaerts B; Kostev K Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643 [TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919 [TBL] [Abstract][Full Text] [Related]
20. Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020-Nationwide Data from a Register-Based Analysis. Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Lengyel C; Kempler P; Wittmann I Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]